Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M Bayssas

Phase I Study of Cinchonine, a Multidrug Resistance Reversing Agent, Combined With the CHVP Regimen in Relapsed and Refractory Lymphoproliferative Syndromes

Leukemia

English

Related publications

Phase IB Study of Doxorubicin in Combination With the Multidrug Resistance Reversing Agent S9788 in Advanced Colorectal and Renal Cell Cancer

British Journal of Cancer

Cancer Research

Oncology

1997

English

Cyclosporine Modulation of Multidrug Resistance in Combination With Pravastatin, Mitoxantrone and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1/2 Study

Leukemia and Lymphoma

English

Pembrolizumab Combined With Lenalidomide and Low‐dose Dexamethasone for Relapsed or Refractory Multiple Myeloma: Phase I KEYNOTE ‐023 Study

British Journal of Haematology

Hematology

2019

English

Cyclosporine Modulation of Multidrug Resistance in Combination With Pravastatin, Mitoxantrone, and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study

English

Single Agent Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer. Phase II Study

Research in Oncology

2007

English

Atacicept in Relapsed/Refractory Multiple Myeloma or Active Waldenström's Macroglobulinemia: A Phase I Study

British Journal of Cancer

Cancer Research

Oncology

2009

English

Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Clinical Lymphoma, Myeloma and Leukemia

English

A Phase II Study of Docetaxel in Patients With Relapsed and Refractory Ewing's Tumours

English

Phase I Study of Romidepsin and Liposomal Doxorubicin in Relapsed or Refractory T-Cell Lymphoma

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M Bayssas

Phase I Study of Cinchonine, a Multidrug Resistance Reversing Agent, Combined With the CHVP Regimen in Relapsed and Refractory Lymphoproliferative Syndromes

Related publications

Phase IB Study of Doxorubicin in Combination With the Multidrug Resistance Reversing Agent S9788 in Advanced Colorectal and Renal Cell Cancer

Cyclosporine Modulation of Multidrug Resistance in Combination With Pravastatin, Mitoxantrone and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1/2 Study

Pembrolizumab Combined With Lenalidomide and Low‐dose Dexamethasone for Relapsed or Refractory Multiple Myeloma: Phase I KEYNOTE ‐023 Study

Cyclosporine Modulation of Multidrug Resistance in Combination With Pravastatin, Mitoxantrone, and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study

Single Agent Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer. Phase II Study

Atacicept in Relapsed/Refractory Multiple Myeloma or Active Waldenström's Macroglobulinemia: A Phase I Study

Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

A Phase II Study of Docetaxel in Patients With Relapsed and Refractory Ewing's Tumours

Phase I Study of Romidepsin and Liposomal Doxorubicin in Relapsed or Refractory T-Cell Lymphoma